This study tests an oral medication called etavopivat in 450 people with sickle cell disease. The goal is to see if it can raise hemoglobin levels and reduce the number of painful vaso-occlusive crises (blocked blood vessels). Participants are randomly assigned to receive the dru…
Phase: PHASE3 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 02:03 UTC